bioAffinity Technologies, Inc. (BIAFW)
bioAffinity Technologies, Inc. (BIAFW)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Fair value adjustment on warrants | NaN | 0 | 2,747,460 | 1,062,818 |
| Net loss | -3,630,610 | -3,137,466 | -5,051,084 | -6,721,204 |
| Depreciation and amortization | 114,518 | 123,659 | 113,360 | 267,817 |
| Stock-based compensation expense | 14,340 | 66,119 | 67,132 | 538,223 |
| Accounts and other receivables | 143,274 | 92,972 | 27,121 | -717,335 |
| Inventory | 24,339 | 18,314 | -8,737 | 16,363 |
| Prepaid expenses and other assets | -40,002 | 59,729 | 60,037 | -29,706 |
| Accounts payable | 74,310 | -178,860 | -229,076 | 182,526 |
| Accrued expenses | 310,857 | 733,442 | -63,487 | -350,688 |
| Unearned revenue | -11,265 | 4,490 | 13,511 | 0 |
| Operating lease right-of-use asset | -28,221 | -68 | -307 | -849 |
| Net cash used in operating activities | -3,227,240 | -2,559,563 | -2,480,298 | -4,288,981 |
| Proceeds from exercised stock options | NaN | NaN | NaN | 0 |
| Purchase of property and equipment | 5,663 | 1 | -3,646 | 64,213 |
| Proceeds from loans payable | NaN | NaN | NaN | 0 |
| Net cash used in investing activities | -5,663 | -1 | 3,646 | -64,213 |
| Proceeds from issuance of common stock from direct offering | NaN | 1,800,000 | 6,473,180 | 2,798,354 |
| Proceeds from exercise of warrants | NaN | 285 | 3,255,166 | 1,558,576 |
| Proceeds from issuance of convertible preferred stock | NaN | 0 | 990,000 | NaN |
| Payment of offering costs for financing activities | NaN | 353,480 | 1,418,459 | NaN |
| (payments) proceeds from loans payable | NaN | -45,375 | NaN | NaN |
| Payment on loans payable | 29,544 | NaN | -101,156 | 112,951 |
| Principal repayments on finance leases | 77,174 | 73,074 | 58,031 | 193,241 |
| Net cash (used) provided by financing activities | -118,513 | 1,340,151 | 9,343,012 | 4,050,738 |
| Net decrease in cash and cash equivalents | -3,351,416 | -1,219,413 | 6,866,360 | -302,456 |
| Cash and cash equivalents at beginning of period | 6,449,782 | 7,669,195 | 1,105,291 | NaN |
| Cash and cash equivalents at end of period | 3,098,366 | 6,449,782 | 7,669,195 | NaN |